AbbVie Inc. $ABBV Shares Purchased by Vise Technologies Inc.

Posted by Geri Gentry on Nov 1st, 2026

Vise Technologies Inc. increased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 21.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 143,948 shares of the company’s stock after purchasing an additional 25,704 shares during the quarter. Vise Technologies Inc.’s holdings in AbbVie were worth $37,655,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Investment Partners LTD. increased its holdings in AbbVie by 82.2% during the third quarter. Investment Partners LTD. now owns 10,925 shares of the company’s stock worth $2,858,000 after buying an additional 4,928 shares during the last quarter. Global Assets Advisory LLC raised its stake in AbbVie by 1.7% during the 3rd quarter. Global Assets Advisory LLC now owns 7,625 shares of the company’s stock worth $2,008,000 after buying an additional 126 shares during the period. Summit Global Investments lifted its holdings in shares of AbbVie by 45.1% in the third quarter. Summit Global Investments now owns 16,792 shares of the company’s stock valued at $4,393,000 after purchasing an additional 5,220 shares in the last quarter. Coyle Financial Counsel LLC increased its position in shares of AbbVie by 3.1% during the third quarter. Coyle Financial Counsel LLC now owns 8,020 shares of the company’s stock valued at $2,098,000 after acquiring an additional 240 shares during the last quarter. Finally, Sagace Wealth Management LLC purchased a new stake in shares of AbbVie during the 3rd quarter worth approximately $235,000. 70.23% of the stock is owned by institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Stock Up 1.4%

AbbVie stock opened at $294.80 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $298.74. The firm has a fifty day moving average of $269.35 and a 200-day moving average of $237.23. The firm has a market capitalization of $520.85 billion, a P/E ratio of 50.74, a PEG ratio of 1.35 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.86 earnings per share. On average, research analysts expect that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Cantor Fitzgerald lifted their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. The Goldman Sachs Group boosted their price objective on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Barclays lifted their price objective on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. Finally, Leerink Partners raised their target price on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $279.86.

View Our Latest Stock Report on AbbVie

About AbbVie

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.